# Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients

> **NCT04111367** · PHASE2 · UNKNOWN · sponsor: **Ginkgopharma CO., LTD** · enrollment: 36 (estimated)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Seraprevir
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT04111367
- **Lead sponsor:** Ginkgopharma CO., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-03
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-08-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04111367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04111367, "Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04111367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*